For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220622:nRSV6928Pa&default-theme=true
RNS Number : 6928P Directa Plus PLC 22 June 2022
22 June 2022
Directa Plus plc
("Directa Plus" or the "Company")
Grant of Italian Patent for Filtration Applications
Directa Plus (AIM: DCTA), a leading producer and supplier of graphene
nanoplatelets based products for use in consumer and industrial markets,
announces that the Company has been granted an Italian patent covering the use
of the Company's G+® pristine graphene nanoplatelets applied to textile
substrates for high bacterial filtration efficiency media for filtration
applications. The priority date for the patent is 25 May 2020.
G+® applied to textile substrates provides proven antibacterial and antiviral
(including anti-SARS-CoV-2) performance. The target filtration market
applications cover both medical and industrial use. Directa Plus started
work on air filtration in 2020 with a signature project that successfully
supplied face masks with anti-SARS-CoV-2 protection. This work led quickly
into exploring industrial filtration applications starting with the automotive
and HVAC (heating, ventilation and air conditioning) markets. Directa Plus,
as already announced, has partnered with a leading worldwide supplier of
non-woven textile materials to develop a suite of new products for automotive
and industrial applications based on the antimicrobial properties
(antibacterial and antiviral), thermal comfort and electrical conductivity
properties of G+® enhanced fabrics.
Following the grant of the patent, Directa Plus's IP portfolio comprises 20
patent families with 73 patents granted and 28 patents pending.
Commenting, Giulio Cesareo, Founder and CEO of Directa Plus, said: "The grant
of a patent for a new market vertical demonstrates the speed with which we can
enter existing high potential markets to supply innovative new products. The
international filtration markets are large and we believe that there will be
significant demand for proven antimicrobial products which we aim to launch
quickly with our industrial partners."
For further information please visit http://www.directa-plus.com/
(http://www.directa-plus.com/) or contact:
Directa Plus plc +39 02 36714458
Giulio Cesareo, CEO / Giorgio Bonfanti, CFO
Cenkos Securities plc (Nominated Adviser and Joint Broker) +44 131 220 6939
Neil McDonald / Adam Rae
Singer Capital Markets (Joint Broker) +44 20 7496 3069
Rick Thompson / Phil Davies
Tavistock (Financial PR and IR) +44 20 7920 3150
Simon Hudson / Heather Armstrong
About Directa Plus
Directa Plus (www.directa-plus.com) is one of the largest producers and
suppliers of graphene-based products for use in consumer and industrial
markets. The Company's graphene manufacturing capability uses proprietary
patented technology based on a plasma super expansion process. Starting from
natural graphite, each step of Directa Plus' production process - expansion,
exfoliation and drying - creates graphene-based materials and hybrid graphene
materials ready for a variety of uses and available in various forms such as
powder, liquid and paste.
This proprietary production process uses a physical process, rather than a
chemical process, to process graphite into pristine graphene nanoplatelets,
which enables Directa Plus to offer a sustainable, non-toxic product, without
unwanted by-products. Directa Plus' products are made of hybrid graphene
materials and graphene nano-platelets. The products (marketed as G+®) have
multiple applications due to its properties. These G+® products can be
categorised into various families, with different products being suitable for
specific practical applications.
Directa Plus was established in 2005 and is based in Lomazzo (Como, Italy) and
has been listed on the AIM market of the London Stock Exchange since May 2016.
The Company holds the Green Economy Mark from London Stock Exchange which
recognises companies that contribute to the global green economy.
-ends-
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAFBMATMTITBTT